See more : Excelsior Medical Co., Ltd. (4104.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Zymergen Inc. (ZY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zymergen Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Quizam Media Corporation (QQQFF) Income Statement Analysis – Financial Results
- Stevanato Group S.p.A. (STVN) Income Statement Analysis – Financial Results
- Beijing Centergate Technologies (holding) Co., Ltd. (000931.SZ) Income Statement Analysis – Financial Results
- Yihai Kerry Arawana Holdings Co., Ltd (300999.SZ) Income Statement Analysis – Financial Results
- Centurion Minerals Ltd. (CTN.V) Income Statement Analysis – Financial Results
Zymergen Inc. (ZY)
About Zymergen Inc.
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 16.74M | 13.28M | 15.42M |
| Cost of Revenue | 69.72M | 84.82M | 102.64M |
| Gross Profit | -52.98M | -71.53M | -87.22M |
| Gross Profit Ratio | -316.42% | -538.50% | -565.67% |
| Research & Development | 159.12M | 90.85M | 50.72M |
| General & Administrative | 83.01M | 60.08M | 61.25M |
| Selling & Marketing | 23.65M | 18.63M | 24.14M |
| SG&A | 106.66M | 78.70M | 85.39M |
| Other Expenses | 175.51M | 0.00 | 0.00 |
| Operating Expenses | 265.78M | 169.56M | 136.10M |
| Cost & Expenses | 335.50M | 254.37M | 238.74M |
| Interest Income | 64.00K | 492.00K | 4.92M |
| Interest Expense | 14.71M | 10.96M | 2.94M |
| Depreciation & Amortization | 20.70M | 18.71M | 15.20M |
| EBITDA | -326.33M | -232.58M | -218.65M |
| EBITDA Ratio | -1,949.08% | -1,750.80% | -1,418.08% |
| Operating Income | -347.03M | -241.09M | -237.11M |
| Operating Income Ratio | -2,072.68% | -1,814.88% | -1,537.80% |
| Total Other Income/Expenses | -14.71M | -21.15M | 318.00K |
| Income Before Tax | -361.73M | -262.24M | -236.80M |
| Income Before Tax Ratio | -2,160.51% | -1,974.13% | -1,535.74% |
| Income Tax Expense | 51.00K | -49.00K | 8.00K |
| Net Income | -361.79M | -262.19M | -236.80M |
| Net Income Ratio | -2,160.81% | -1,973.76% | -1,535.79% |
| EPS | -4.87 | -2.68 | -2.42 |
| EPS Diluted | -4.87 | -2.68 | -2.42 |
| Weighted Avg Shares Out | 74.31M | 97.94M | 97.94M |
| Weighted Avg Shares Out (Dil) | 74.31M | 97.94M | 97.94M |
ZY LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Zymergen Inc.
New York, New York--(Newsfile Corp. - September 30, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Zymergen Inc. (NASDAQ: ZY) ("Zymergen"). This lawsuit is on behalf of...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymergen, Inc. - ZY
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymergen, Inc. ("Zymergen or the "Company") (NASDAQ: ZY).
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Zymergen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2021 - ZY
New York, New York--(Newsfile Corp. - September 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Zymergen Inc. ("Zymergen") (NASDAQ: ZY) This lawsuit is...
ZY MONDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Zymergen Inc. Class Action Lawsuit
San Diego, California--(Newsfile Corp. - September 29, 2021) - Robbins Geller Rudman & Dowd LLP announces that purchasers of Zymergen Inc. (NASDAQ: ZY) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in...
ZY MONDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Zymergen Inc. Class Action Lawsuit
San Diego, California--(Newsfile Corp. - September 29, 2021) - Robbins Geller Rudman & Dowd LLP announces that purchasers of Zymergen Inc. (NASDAQ: ZY) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in...
ZY Investor Alert: Shareholder Class Action Lawsuit Filed
Boston, Massachusetts--(Newsfile Corp. - September 29, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Zymergen Inc. (NASDAQ: ZY). The case is currently in the lead plaintiff stage....
ZY Investor Alert: Shareholder Class Action Lawsuit Filed
Boston, Massachusetts--(Newsfile Corp. - September 29, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Zymergen Inc. (NASDAQ: ZY). The case is currently in the lead plaintiff stage....
ZY ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2021 in the Class Action Filed on Behalf of Zymergen Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - September 29, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Zymergen Inc. (NASDAQ: ZY) alleging that the Company violated federal securities laws.This...
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ATVI, ZY and SLQT
NEW YORK, NY / ACCESSWIRE / September 29, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
ZY INVESTOR DEADLINE: Hagens Berman Encourages Zymergen (ZY) Investors with Losses to Contact Firm's Attorneys BEFORE OCTOBER 4TH DEADLINE in Securities Fraud Lawsuit
San Francisco, California--(Newsfile Corp. - September 29, 2021) - Hagens Berman urges Zymergen Inc. (NASDAQ: ZY) investors with significant losses to submit your losses now.Class Period: Apr. 20, 2021 - Aug. 4, 2021Lead Plaintiff Deadline: Oct. 4, 2021Visit: www.hbsslaw.com/investor-fraud/ZY Contact...
Source: https://incomestatements.info
Category: Stock Reports